{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:07:29Z","timestamp":1777727249115,"version":"3.51.4"},"reference-count":46,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100018636","name":"Xuzhou Science and Technology Program","doi-asserted-by":"publisher","award":["KC23341"],"award-info":[{"award-number":["KC23341"]}],"id":[{"id":"10.13039\/501100018636","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nantong University Clinical Medicine Special Scientific Research Fund Project","award":["2024LY006"],"award-info":[{"award-number":["2024LY006"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Gemcitabine plus cisplatin is the standard adjuvant regimen for postoperative management of muscle-invasive upper tract urothelial carcinoma. This study investigated whether adding tislelizumab to gemcitabine plus cisplatin improves outcomes in patients with muscle-invasive upper tract urothelial carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, single-center cohort analysis of consecutive patients who underwent laparoscopic radical nephroureterectomy (April 2020 to April 2025) and received adjuvant gemcitabine plus cisplatin or tislelizumab combined with gemcitabine plus cisplatin within 90 days postsurgery (\u22653 cycles). No patients were lost to follow-up. The observed outcomes were disease-free survival, distant metastasis-free survival, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 67 patients (37, tislelizumab combined with gemcitabine plus cisplatin group; 30, gemcitabine plus cisplatin group), the median follow-up duration was 15.6 months. Median disease-free survival was not reached in the tislelizumab combined with gemcitabine plus cisplatin group compared with 27.1 months in the gemcitabine plus cisplatin group. Tislelizumab combined with gemcitabine plus cisplatin significantly improved disease-free survival (hazard ratio\u2009=\u20090.441, p\u2009=\u20090.035) and distant metastasis-free survival (hazard ratio\u2009=\u20090.389, p\u2009=\u20090.036). Adverse events were comparable between groups, with no severe immune-related toxicities or treatment-related deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adjuvant tislelizumab combined with gemcitabine plus cisplatin demonstrated superior disease-free survival and distant metastasis-free survival compared with gemcitabine plus cisplatin alone, with acceptable safety, supporting further investigation in patients with muscle-invasive upper tract urothelial carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03000605261433777","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:25:41Z","timestamp":1774916741000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tislelizumab combined with gemcitabine plus cisplatin for muscle-invasive upper tract urothelial carcinoma: A retrospective single-center cohort analysis"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0798-4667","authenticated-orcid":false,"given":"Jingwen","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, Nantong First People\u2019s Hospital, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongshuang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Hospital of Xuzhou Medical University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghua","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Hospital of Xuzhou Medical University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, Nantong First People\u2019s Hospital, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Urology, Suining County People\u2019s Hospital, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.013"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.02.023"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.08.021"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2025.06.023"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05032-y"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.04.025"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.003"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193226"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02763"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.139"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14681"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/CU9.0000000000000263"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.13102"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01926"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1833857"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1652917"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231173475"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.04.014"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00108-0"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-01083-8"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.028"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02909-9"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32100558"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.033"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S411751"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152467"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30415-3"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1825376"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.08.001"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1012292"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2025.09.006"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-93557-6"},{"key":"e_1_3_7_37_2","first-page":"162","article-title":"PD-L1 testing for urothelial carcinoma: interchangeability, reliability and future perspectives","volume":"22","author":"Gevaert T","year":"2021","unstructured":"Gevaert T, Cimadamore A, Montironi R, et\u00a0al. PD-L1 testing for urothelial carcinoma: interchangeability, reliability and future perspectives. Curr Drug Targets 2021; 22: 162\u2013170.","journal-title":"Curr Drug Targets"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-019-00572-9"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000001097"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278038"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2022.03.007"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.3892\/or.2025.8970"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100785"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122121"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-1103"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02294-9"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00763"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261433777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605261433777","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261433777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:48:58Z","timestamp":1777459738000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605261433777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/03000605261433777"],"URL":"https:\/\/doi.org\/10.1177\/03000605261433777","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"03000605261433777"}}